For complete information about the report, please visit our website
https://www.reportscorner.com/reports/28660/Onconova-Therapeutics-(ONTX)--Near-Term-Catalysts-=-Upside-Still!/
Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: 5.9m share offering @ $15 July 25, 2013) has been impressive (30% up since IPO), raising the inevitable question – Is this the upper limit or is there still room for upside? Estybon is targeting a niche patient pool, where unmet medical needs remain due to lack of effective treatment or no approved therapies. Rig. IV showed median overall survival of 35 weeks in four early-stage PhI/II trials in pts with 2nd-line Higher Risk MDS vs. less than six months offered by current standard of care (as per historic peer-reviewed published reports). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON 01910.Na, PhIII, PI3K-PLK inhibitor, partnered with Baxter for EU rights and SymBio pharma for Japan & Korean rights) is ... For more detail please read our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"
https://www.reportscorner.com/reports/28660/Onconova-Therapeutics-(ONTX)--Near-Term-Catalysts-=-Upside-Still!/
Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: 5.9m share offering @ $15 July 25, 2013) has been impressive (30% up since IPO), raising the inevitable question – Is this the upper limit or is there still room for upside? Estybon is targeting a niche patient pool, where unmet medical needs remain due to lack of effective treatment or no approved therapies. Rig. IV showed median overall survival of 35 weeks in four early-stage PhI/II trials in pts with 2nd-line Higher Risk MDS vs. less than six months offered by current standard of care (as per historic peer-reviewed published reports). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON 01910.Na, PhIII, PI3K-PLK inhibitor, partnered with Baxter for EU rights and SymBio pharma for Japan & Korean rights) is ... For more detail please read our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"
No comments:
Post a Comment